Aliophen-XP, (poly)phenolic fraction from unfermented malts and hops with antioxidant and preventive activity (acronym Aliophen-XP)

# Record card
293
Thematic areas
Agrifood / Nutrition & health
Agrifood / Food quality & safety
Health & Biotech / Care, Hygiene, Cosmetics
Description

Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.

The increased concentration of bioactive molecules in Aliophen-XP offers significant advantages in terms of biological efficacy. Laboratory studies have demonstrated robust antioxidant activity across various cellular models, including keratinocytes and intestinal cells. Furthermore, chemopreventive effects were observed without detectable toxicity on normal cells. In its patent application, Aliophen-XP is supported by experimental evidence for use as an antioxidant, antitumor agent, cosmeceutical ingredient, and dietary supplement for human consumption.

Type of innovation
Product innovation
Process innovation
Description of innovative features / Competitive advantages

Aliophen-XP is an innovative and multifunctional formulation that leverages natural ingredients with a high concentration of bioactive molecules, offering exceptional antioxidant and chemopreventive benefits. Its distinctive feature lies in the elevated concentration of polyphenols and other bioactive compounds, extracted naturally from malt and hops. These ingredients, well-known for their beneficial properties, are rarely utilized in such highly concentrated forms, enabling a more targeted and effective action compared to conventional antioxidant formulations on the market. The unique characteristics of Aliophen-XP ensure its versatility, making it suitable for a wide range of applications and ideal for developing cutting-edge products. Additionally, the formulation is free from components that might interfere with the biological activity of its bioactive molecules, enhancing its efficacy. This high concentration amplifies the biological properties of the original Aliophen® formulation, enabling more precise targeting of specific action areas and broadening its potential applications, particularly in preventing common pathologies and supporting overall wellness.

Reference market
Incremental innovation
Impacts on existing markets
Creation of new markets
Development stage
Feasibility
TRL
3
4
Advantages
New product/process/service/technology
Product/process/service/technology optimization
Patented technology
Yes
Country/ies

Italy

Publication of technology
Published
Technology validation/demonstration
Internal validation
Market positioning
Italian
European
International
Partner required
Public research center/university
Private research center
Seed capital
Cooperation in national /european / international project

Information
For more information and/or to be put in contact with the Research Team, please contact the Project Manager:

Barbara Angelini - Project Manager
CNR - Unità Valorizzazione della Ricerca
Phone number 06.49932415
E-mail barbara.angelini@cnr.it